Diversified Consumer Services
Company Overview of University of Southampton
University of Southampton is an educational institution. It offers undergraduate, postgraduate, and postgraduate research courses. The university was formerly known as Hartley University College and changed its name to University of Southampton in April 1952. The university was founded in 1862 and is based in Southampton, United Kingdom.
Southampton, SO17 1BJ
Founded in 1862
Key Executives for University of Southampton
Compensation as of Fiscal Year 2015.
University of Southampton Key Developments
URI Graduate School of Oceanography Initiates Partnership with University of Southampton for Research, Education
Jun 24 15
Faculty and students from the University of Rhode Island's Graduate School of Oceanography will soon begin a series of visits to the University of Southampton in England as part of a new partnership recently formalized by the two institutions. Following a year of discussions and preliminary visits, the collaboration was formalized this June with the signing of a memorandum of understanding between the two universities. The agreement leaves open the possibility of expanding the relationship in the future to a wide variety of academic disciplines beyond oceanography. The partnership will begin this summer with a faculty exchange program that will involve two URI scientists visiting the National Oceanographic Centre Southampton and one scientist from Southampton traveling to Narragansett. The first exchange will take place Aug. 1 through 7 when Dwight Coleman, a marine research scientist and director of the Inner Space Center at the URI Bay Campus, will visit the University of Southampton. He manages the URI telepresence technology, which broadcasts live images of oceanographic research from ships around the world to the Inner Space Center. Coleman will explore the possibility of implementing the technologies on the ships operated by the University of Southampton to expand the network of research vessels that broadcast their activities to the Inner Space Center.
BioInvent International to Collaborate with University of Southampton Under Three Year Research Agreement
Jun 2 15
BioInvent International announced that it has entered into a three-year research collaboration with the University of Southampton (UoS), under the direction of Professor Mark Cragg, professor of Experimental Cancer Research and director of the Cancer Pathway Integrated Postgraduate Programme. This collaboration, also involving Professor Martin Glennie and Dr. Stephen Beers, is aimed at developing new immunotherapy treatments for cancer by targeting regulatory T cells (T regs). According to the company, this programme builds on the clinical successes of antibodies to so called T cell checkpoint inhibitors. Also, this collaboration aims to develop novel antibodies and targets that are more specific for the cancer-associated T regs. Reportedly, this collaboration is separate from two existing research programmes in place between the University of Southampton and BioInvent. Under this collaboration, terms of which were not disclosed, BioInvent will have the option to license any promising results for further development and commercialisation. Also, under this agreement, both parties will contribute to intellectual property generation.
BioInvent International and Cancer Research Technology Ltd Sign Two-Year Research Collaboration with University of Southampton
Apr 9 15
BioInvent International and Cancer Research Technology Ltd. (CRT) have signed two-year research collaboration with the University of Southampton. The program aims to develop new immunotherapy treatments for cancer based on preclinical work by the Southampton group showing the potential to treat cancer using antibodies targeting OX40 and 4-1BB - known 'co-receptors' that help stimulate the production of killer T-cells during an immune response. One of the ways that tumour cells avoid detection is by suppressing immune responses to stop functional tumour specific T-cells from being produced. The team aims to develop antibodies that can reverse this process to stimulate the immune system to fight the cancer. Terms of the collaboration were not disclosed, however, BioInvent has the option to take out a license to commercialize any promising results, with the parties receiving milestone payments and a share of potential revenues. The first phase of the project aims to identify and then validate the effectiveness of the best class of antibodies to target OX40 and 4-1BB. This work will be carried out in Lund, Sweden, and Southampton, UK, using highly specialised assays and expertise developed through a prior long-standing collaboration between BioInvent and the University of Southampton.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 30, 2015